C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
C4 Therapeutics's enterprise value was $54.80M on Nov 11, 2026, against $1.21M a year earlier. Over the last 5 years it ranged from -$203.26M to $1.09B, with a median of $1.21M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $54.80M | – |
| 2025 | Dec 31, 2025 | -$58.13M | – |
| 2024 | Dec 31, 2024 | -$30.37M | -195.2% |
| 2023 | Dec 29, 2023 | $31.92M | – |
| 2022 | Dec 30, 2022 | -$65.89M | -106.0% |
| 2021 | Dec 31, 2021 | $1.09B | – |
| 2020 | Dec 31, 2020 | -$135.38M | – |
See a number that looks wrong?